Mississippi will receive $18.5 million from drug maker Eli Lilly and Co. as part of a settlement over claims the company promoted the anti-psychotic Zyprexa for ailments it was not federally approved to treat, Attorney General Jim Hood said Thursday. The settlement recovers money the state spent through its Division of Medicaid and the State Insurance Plan, Hood said. The company also will pay $3.7 million in legal fees for the state.
via dddmag.com
2 comments:
Eli Lilly has made $40 billion on $10 a pill Zyprexa and it was way oversold and caused diabetes and in some cases sudden death.
Zyprexa was pushed by Lilly Drug Reps.
They called it the "Five at Five" (5 mg at 5 pm to keep nursing home patients subdued and sleepy) and "VIVA ZYPREXA" (Zyprexa for everybody) campaigns to off label market Eli Lilly Zyprexa as a fix for unapproved usage.
--
Daniel Haszard
http://www.zyprexa-victims.com
I wonder if any group tracks the free meds that are given to community mental health clinics by drug reps.
County mental health clinics are always under budget restrictions so accepting "samples" of drugs for their patients is a common practice. The drugs are then prescribed by psychiatrists on staff for low income or indigent clients who could not afford them on their own.
This may play havoc with medication distribution numbers. Any therapist knows that such clients are more likely to have erratic appointment schedules and often, through no fault of their own, suffer an inability to get a timely appointment. Sliding scale or free clinics would have inaccurate or no reports of side-effects. Often patients just quit using a medication that bothers them. Unless a client is seen regularly, drug complaints go undocumented.
The management of chronic mental illness via sample drugs frequently occurs among a poor population that is difficult to track accurately, which could lead to the pharmaceutical company presenting their drug as trouble-free. Does the FDA ever track these unusual distributions?
Post a Comment